4N Disease-free survival in breast cancer patients with minimal lymph node involvement: results in 241 isolated tumour cells or micrometastases in the sentinel lymph node with negative complementary axillary dissection

Objective: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Brazilian cohort and identify potential prognostic factors. Methods: This hospital-based retrospective cohort study included 447 women with breast cancer treated at referral centers in Southeastern Brazil. Overall and disease-free survival were compared; prognostic factors were evaluated. Results: Triple-negative breast cancer corresponded to 19.5% of breast cancer diagnosis and was more prevalent among nonwhite and less educated women. The patients with TNBC tended to present with stage III cancer, high p53 expression, lymphocytic infiltration, and multifocality and treated with radical surgery and chemotherapy. The 5-year overall and disease-free survival were 62.1% and 57.5% for TNBC and 80.8% and 75.3% for non-TNBC, respectively ( P < .001). The TNBC recurrence was associated with multicentricity, whereas lymph node involvement increased the risk of both recurrence and death. Non-TNBC worse clinical course was associated with nonwhite ethnicity, lower education level, lymph node involvement, and advanced stage. Conclusions: Triple-negative breast cancer exhibited a more aggressive behavior, earlier and more frequent recurrence, and worse survival compared with non-TNBC. While biological and social variables were associated with poorer prognosis in non-TNBC, only lymph node involvement and multicentricity were correlated with worse clinical outcomes in TNBC.

Download Full-text

Circulating resistin in early-onset breast cancer patients with normal body mass index correlate with disease-free survival and lymph node involvement

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2018.02.184 ◽

2018 ◽

Vol 44 (6) ◽

pp. 905

Author(s):

Bashar Zeidan ◽

Antigoni Manousopoulou ◽

Diana Garay-Baquero ◽

Cory White ◽

Samantha Larkin ◽

...

Keyword(s):

Breast Cancer ◽

Body Mass Index ◽

Disease Free Survival ◽

Lymph Node Involvement ◽

Normal Body Mass Index ◽

Breast Cancer Patients ◽

Early Onset Breast Cancer ◽

Free Survival ◽

Node Involvement ◽

Disease Free

Download Full-text

Triple-negative and non–triple-negative breast cancer in a south Indian cohort.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e13110 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e13110-e13110

Author(s):

Narayanankutty Edavalath Warrier ◽

Uma V Sankar ◽

Sreedharan P S ◽

Ajmal Sherif

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Triple Negative Breast Cancer ◽

Rural Women ◽

Triple Negative ◽

Disease Free Survival ◽

Lymph Node Involvement ◽

Free Survival ◽

Node Involvement ◽

Disease Free

e13110 Background: The heterogeneity of breast cancer explains in part the differences in the morbidity and mortality of this disease. Triple-negative breast cancer (TNBC) is a specific subset of tumors characterized by the absence of the 3 most commonly targeted biomarkers considered for breast cancer treatment: Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2). TNBC accounts for 15% to 20% of all breast cancer diagnoses and usually has a more aggressive clinical course, with worse evolution within the first 3 to 5 years after diagnosis; early and higher rates of distant recurrences, typically visceral; and poor survival. Methods: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Kerala cohort and identify potential prognostic factors. This hospital-based retrospective cohort study (From January 2017 till December 2018) included 465 women with breast cancer treated at MVR Cancer Centre & Research Institute in North Kerala. Overall and disease-free survival was compared; prognostic factors were evaluated. Results: Triple-negative breast cancer corresponded to 16.3% of breast cancer diagnosis and was more prevalent among rural women. The patients with TNBC tended to present with stage III cancer, high p53 expression, lymphocytic infiltration, and multifocality and treated with radical surgery and chemotherapy. The 2-year overall and disease-free survival were 52.1% and 43.5% for TNBC and 83.8% and 73.4% for non-TNBC, respectively ( P < .001). The TNBC recurrence was associated with multicentricity, whereas lymph node involvement increased the risk of both recurrence and death. Non-TNBC worse clinical course was associated with rural women, younger age, lymph node involvement, and advanced stage. Conclusions: Triple-negative breast cancer exhibited a more aggressive behavior, earlier and more frequent recurrence, and worse survival compared with non-TNBC. While biological and social variables were associated with poorer prognosis in non-TNBC, only lymph node involvement and multicentricity were correlated with worse clinical outcomes in TNBC.

Download Full-text

Serum cyfra21-1 associated with biological aggressiveness and poor prognosis in male patients with urothelial carcinoma of bladder.

10.21203/rs.3.rs-20430/v1 ◽

2020 ◽

Author(s):

Haitao Liang ◽

Yunlin Ye ◽

Zhu Lin ◽

Zikun Ma ◽

Lei Tan ◽

...

Keyword(s):

Overall Survival ◽

Lymph Node ◽

Lymphovascular Invasion ◽

Disease Free Survival ◽

Lymph Node Involvement ◽

Free Survival ◽

Node Involvement ◽

Male Patients ◽

Disease Free ◽

Urothelial Carcinoma Of Bladder

Abstract Background : To assess the prognostic value of preoperative serum cyfra21-1 in male patients with urothelial carcinoma of bladder treated with radical cystectomy.Methods: Patients underwent radical cystectomy from 2009-2018 at our center were retrospectively analyzed and 267 male patients met our criterions. The median follow-up was 34 months. The serum level of cyfra21-1 was measured using enzyme linked immunosorbent assay. Patients were divided into two groups (cyfra21-1≤3.30ng/ml and cyfra21-1>3.30 ng/ml). Clinical significance of cyfra21-1 level was assessed.Results: Of the 267 patients, 110 (41.2%) had normal cyfra21-1, while 157 (58.8%) had elevated serum cyfra21-1. The prevalence of lymph node involvement, locally advanced stage (≥ pT3), tumor stages, tumor size and papillary were significantly higher in patients with elevated cyfra21-1 than in those with normal cyfra21-1. Patients with high cyfra21-1 showed worse Disease free survival and Overall survival than those with low cyfra21-1 ( P = 0.001 and 0.007, respectively). In multivariate analysis, High cyfra21-1, lymph node involvement, lymphovascular invasion and papillary were independent predictors of worse Disease free survival ( P = 0.036, <0.001, 0.002, 0.014 respectively). High cyfra21-1, lymph node involvement and lymphovascular invasion were also confirmed as independent predictors of worse Overall survival ( P = 0.038, 0.010, 0.005, respectively.)Conclusions: Elevated cyfra21-1 was associated with greater biological aggressiveness and worse prognosis than normal cyfra21-1.

Download Full-text